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ABSTRACT: Src homology 2 domain-containing inositol phosphate phospha-
tase 2 (SHIP2) is one of the 10 human inositol phosphate 5-phosphatases. One
of its physiological functions is dephosphorylation of phosphatidylinositol 3,4,5-
trisphosphate, PtdIns(3,4,5)P3. It is therefore a therapeutic target for
pathophysiologies dependent on PtdIns(3,4,5)P3 and PtdIns(3,4)P2. Ther-
apeutic interventions are limited by the dearth of crystallographic data
describing ligand/inhibitor binding. An active site-directed fluorescent probe
facilitated screening of compound libraries for SHIP2 ligands. With two
additional orthogonal assays, several ligands including galloflavin were identified
as low micromolar Ki inhibitors. One ligand, an oxo-linked ethylene-bridged
dimer of benzene 1,2,4-trisphosphate, was shown to be an uncompetitive
inhibitor that binds to a regulatory site on the catalytic domain. We posit that
binding of ligands to this site restrains L4 loop motions that are key to
interdomain communications that accompany high catalytic activity with
phosphoinositide substrate. This site may, therefore, be a future druggable target for medicinal chemistry.
■ INTRODUCTION
Multiple mammalian enzymes share a conserved (inositol) 5-
phosphatase domain, and these include INPP5A, INPP5B,
INPP5E, INPP5J, OCRL, SKIP, Synaptojanin 1, Synaptojanin
2, SHIP1, and SHIP2.1,2 While the physiological substrates of
these enzymes are not all clearly defined some, for example,
SHIP1 and SHIP2, that act physiologically on PtdIns(3,4,5)P3
have become therapeutic targets, not least because of the
restricted expression of SHIP1 in blood cell lineages.3 Because
of this, there remains considerable interest in tools enabling
identification of small molecules that influence the activity of
specific enzymes.4,5 These small molecules may be inhibitors
or activators and may also represent active site (orthosteric) or
allosteric modulators. Inhibitors and/or activators have been
identified for SHIP1 and SHIP2 and for OCRL and the related
enzyme INPP5B.6−15
Irrespective of the mode of inhibition or activation of
inositide- or phosphoinositide-metabolizing enzymes, the
efficacy of inhibitors or activators reflects binding and
subsequent catalytic processing of the bound inositide/
phosphoinositide substrate. There remains an unmet need
for development of assays that can distinguish between the
sites of binding of substrates, substrate analogues, inhibitors,
and activators whether to the active or allosteric sites.
Here, a direct fluorescence polarization (FP) methodology16
is shown to be suitable for characterization of phosphoinositide
phosphatases such as SHIP2. The FP approach involves
displacement of a fluorescent probe from the protein with a
competing ligand or allosteric regulator. We note prior
description of measurement of lipid phosphatase reaction
products by indirect end-point competition assays employing
FP probes.12,17 By the use of orthogonal approaches, several
lead compounds are identified. Simple phosphate release and
HPLC assays confirm the lead compounds to be potent
inhibitors of SHIP2. The HPLC approach, itself, obviates the
use of radiolabeled substrate and is able to confirm specifically
inhibition of the 5-phosphatase activity of SHIP2. Finally,
using a structural biology approach, we solve the structure of a
SHIP2 catalytic domain in complex with a bound dimeric
ligand and potent inhibitor. Binding of the ligand engages a
critical residue that was recently shown to underlie allosteric
control of the catalysis by C2-domain interaction with the
phosphatase domain.18 Our study reveals a potentially
druggable allosteric site on the enzyme.
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■ RESULTS AND DISCUSSION
2-FAM-InsP5 Binds to SHIP2 at the Catalytic Site. 2-
FAM-InsP5 has been shown to be a promising active-site probe
of both inositol pentakisphosphate 2-kinase19 and human
SHIP2.16 Figure 1A compares the structure of 2-FAM-InsP5
with the physiological substrate PtdIns(3,4,5)P3, its water-
soluble head group, Ins(1,3,4,5)P4, and Ins(1,3,4,5,6)P5. For
human SHIP2, 2-FAM-InsP5 enabled identification of catalytic
activity against benzene phosphate surrogates of inositide
substrates.16 Here, we explore the binding of 2-FAM-InsP5 to
the catalytic domain of human SHIP2 in greater detail,
hereafter SHIP2cd. This was determined by measurement of
probe polarization as a function of protein concentration,
yielding an EC50 of 121 nM (Figure 1B). Products of
prolonged incubation of 2-FAM-InsP5 at the substrate level
(50 μM) were analyzed by anion-exchange HPLC with
fluorescence detection at the fluorescein emission wavelength.
2-FAM-InsP5 appeared as a single peak by HPLC and was
converted in an enzyme-dependent manner into products
resolvable by HPLC (Figure 1C), confirming that, under
prolonged incubation, it is a substrate. In the absence of
potential product(s) for use as chromatographic standards
from chemical synthesis, we are unable to identify the product
of enzyme action.
In an attempt to confirm active-site binding of 2-FAM-InsP5,
we undertook crystallography and solved an apo crystal
structure of SHIP2cd (PDB 6SRR, Table S2), but despite
extensive attempts at cocrystallization or soaking with 2-FAM-
InsP5, we did not obtain complexes with this ligand. Instead,
we turned to an in silico docking approach using the apo
structure (PDB 6SRR) as the receptor with 2-FAM-InsP5 as a
flexible ligand. The binding modes all placed the inositol
phosphate ring into the active-site region of SHIP2cd and were
studied for their positioning of phosphates close to the active-
site catalytic residues. In the absence of an inositide substrate-
liganded structure for SHIP2, detailed structural study of the
close family member INPP5B20 has identified a number of
residues conserved among the 5-phosphatase family including
(for SHIP2) K541, S654, Y661, R682, and N684 that likely
coordinate phosphate and hydroxyl substituents of inositide
substrates. The lowest energy-binding pose predicted (Figure
1D) places the P4-phosphate of 2-FAM-InsP5 close to catalytic
residues H718 and D607 and the FAM moiety contacting
K541, projected between the L2 loop and the loop near S564.
These reflect the predicted contacts of the phosphates and
lipid chains of di-C8-PtdIns(3,4,5)P3, respectively (PDB
5OKM18). More than half of the binding modes share a
similar position for the FAM moiety. A further low energy pose
lying only 1.1 kcal mol−1 above this predicted 2-FAM-InsP5 to
Figure 1. Active-site binding of 2-FAM-InsP5 to SHIP2cd. (A) Structures of SHIP2 substrates and 2-FAM-InsP5. (B) Isotherm for binding of 2-
FAM-InsP5 to SHIP2cd. (C) Catalytic processing of 2-FAM-InsP5 incubated with (gray) or without (black) SHIP2cd; different amounts of sample
were injected. (D, E), Docking simulations of 2-FAM-InsP5 binding to apo SHIP2cd reveal binding modes which place phosphates P3 and P4 close
to the catalytic residues H718 and D607.
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be bound in a very similar position with regards to the inositol
phosphate ring, where P4 is close to H718 and P3 is close to
D607 (Figure 1E). However, this binding mode placed the
FAM moiety in the opposite orientation to that described
(Figure 1D) and into the channel created by a loop, L4,
comprising residues 674−684.
These docking results, together with polarization and HPLC
data suggest that 2-FAM-InsP5 has ample room to bind in the
active site and, further to this, can place a phosphate close
enough to the active-site catalytic residues H718 and D607 to
allow hydrolysis to occur. It is not clear whether this is a single
discrete phosphate or whether the enzyme is capable of
removing several phosphates sequentially. While the unavail-
ability of potential hydroxy-substituted products limits further
analysis, a wider family of FAM/FITC-derivatized InsPs was
tested as active-site probes (Table S1), confirming preferential
binding of the most highly phosphorylated ligands and
indicative perhaps of different binding orientations. The very
slow metabolism of 2-FAM-InsP5 that we observed is
consistent with the lack of use by SHIP2 of Ins(1,3,4,5,6)P5
as the substrate; Ins(1,2,3,4,5)P5 is the best substrate.
21
Metabolism does however identify 2-FAM-InsP5 as an active-
site ligand. This important property allows use of 2-FAM-InsP5
in active-site targeted screens. Consequently, we tested the
ability of Ins(1,3,4,5)P4, a commonly assayed substrate in
screens for inhibition of phosphatase activity,10 to displace 2-
FAM-InsP5 and obtained an IC50 of 2300 nM (Figure 2, Table
1).
We additionally included a number of compounds that some
of us have described previously as inhibitors of SHIP2,22
antagonists of IP3R,
23 and stabilizing ligands of 5-phospha-
tases.20 Among these inositol phosphate surrogates, biphenyl
2,3′,4,5′,6-pentakisphosphate [BiPh(2,3′,4,5′,6)P5]24 (1) is the
only ligand (substrate, analogue, or inhibitor) solved in a
crystal structure bound to SHIP2 so far.22 Here, BiPh-
(2,3′,4,5′,6)P5 (1) displaced the probe with an IC50 of 29
Figure 2. Displacement of 2-FAM-InsP5 from SHIP2. (A) BiPh(2,3′,4,5′,6)P5 (1), (B) BiPh(2,2′,4,4′,5,5′)P6 (2), (C) BiPh(3,3′,4,4′,5,5′)P6 (3),
(D) 6,6′-F2-BiPh(3,3′,4,4′)P4 (4), (E) 1,2,4-dimer (5), and (F) Ins(1,3,4,5)P4. Means with SD.
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nM (Figure 2A), very similar to values obtained with the
closely related molecules biphenyl 2,2′,4,4′,5,5′-hexakisphos-
phate [BiPh(2,2′,4,4′,5,5′)P6] (2), 27 nM, and biphenyl
3,3′,4,4′,5,5′-hexakisphosphate [BiPh(3,3′,4,4′,5,5′)P6] (3),
23 nM, (Figure 2B,C). We also introduce and evaluate here
the novel related analogue 6,6′-difluoro biphenyl 3,3′,4,4′-
tetrakisphosphate [6,6′-F2-BiPh(3,3′,4,4′)P4] (4), in which
one of the phosphates (on each ring) has been replaced by a
fluorine; this compound gave an IC50 of 61 nM (Figure 2D).
The related compound, 5,5′-ethane-1,2-diylbis(oxy)bis(ben-
zene-1,2,4-trisphosphate)20 (5) (hereafter named 1,2,4-dimer),
is a bridged dimer of the surrogate ligand of IP3Rs, benzene
1,2,4-trisphosphate. It bears lipid headgroup mimics separated
by a spacer rather than directly through a biphenyl-type
structure. It gave an IC50 of 31 nM (Figure 2E).
The similarities of IC50 for all except the difluoro compound
shows that the additional phosphate(s), missing in the difluoro
compound, contributes to tighter binding. Indeed, the
physiological substrate, PtdIns(3,4,5)P3 also provides three
monoester phosphates on its single ring. All the biphenyl and
related compounds were more potent displacers of 2-FAM-
InsP5 than Ins(1,3,4,5)P4 (Figure 2F).
The biphenyl-type phospholipid headgroup surrogates are
clearly not druglike in nature. The successful binding of 2-
FAM-InsP5 to SHIP2 and its displacement by substrates and
substrate analogues led us therefore to screen the NCI
Diversity set II, Developmental Therapeutics Program NCI/
NIH, and the NCI Approved Oncology Drug (AOD) Set
before developing assays in 384-well microtiter plates.
Previously, for inositol pentakisphosphate 2-kinase, we were
successful in identifying nonphosphate-containing ligands that
could substitute in polyphosphate binding sites.19 Here,
compounds were tested as singletons at 10 μM concentration
in 0.1% DMSO for their ability to displace 2-FAM-InsP5 (5
nM) from 100 nM protein in a 100 μL volume.19
We also tested 3α-aminocholestane (6), a selective inhibitor
of SHIP1, and AS1949490 (7), a selective inhibitor of
SHIP26,7,10 (Figure S1). 3α-Aminocholestane (6) increased
polarization of the probe but did so in the absence of protein.
We attribute this to aggregation of 2-FAM-InsP5 into
compound micelles. AS1949490 also interfered in the FP
assay. From the AOD set, both bosutinib (8) and crizotinib
(9) (Figure S1), the latter with a reported IC50 of 5.5 μM for
inhibition of SHIP2,13 similarly increased polarization of the
probe. Compounds that reduced polarization below 100 mP
were taken forward for dose−response analysis in the range 1
nM−100 μM in 384-well plates. Diversity Set II yielded
purpurogallin (10) and galloflavin (11) as displacing ligands
with IC50s of 5.5 μM and approximately 500 μM (Figure
3B,C), while the AOD set yielded estramustine phosphate
(12) with IC50 35.5 μM (Figure 3D). Mindful of the possibility
of identification of “false-positives” by virtue of undefined
interactions in the polarization assay, we constructed two
secondary screens.
We performed assays of the ability of purpurogallin (10),
galloflavin (11), estramustine phosphate (12), AS1949490 (7),
and 5,6,7,8,4′-pentahydroxyflavone (13) to inhibit the Ins-
(1,3,4,5)P4 phosphatase activity of SHIP2, measured as release
of phosphate. Galloflavin (11), 5,6,7,8,4′-pentahydroxyflavone
(13), and AS1949490 (7) gave IC50 < 10 μM (1.8, 6.0, and 1.5
μM, respectively) (Table 1). The value for AS1949490 (7) is
similar to the 0.44 ± 0.19 μM Ki for inhibition of phosphate
release from Ins(1,3,4,5)P4 reported for this compound
10 and
the identical value 0.44 ± 0.07 μM reported for the related
compound AS1938909.14 Neither compound has been crystal-
lized with SHIP2, but others have docked AS1938909 with
modeled SHIP2 (PDB 4A9C) and report poses of AS1938909
and crizotinib (9) in the active site.13 The biphenyl phosphates
and related compounds were comparable inhibitors to
galloflavin (11) and AS1949490 (7), yielding IC50s for
BiPh(2,3′,4,5′,6)P5 (1), 3.6 μM; BiPh(2,2′,4,4′,5,5′)P6 (2),
1.6 μM; BiPh(3,3′,4,4′,5,5′)P6 (3), 1.0 μM; 6,6′-F2-BiPh-
(3,3′,4,4′)P4 (4), 19.1 μM; and 1,2,4-dimer (5), 11.0 μM
(Figure 4).
Nevertheless, we sought alternative validation of the
inhibitors identified in the prior two screens. Because neither
the 2-FAM-InsP5 FP nor phosphate-release assays testify to the
specificity of phosphatase attack on the Ins(1,3,4,5)P4
substrate, we further used postcolumn metal-complexation
HPLC to confirm the efficacy of inhibitors identified above.
HPLC confirmed SHIP2-catalyzed production of Ins(1,3,4)P3
(Figure S2), inhibited by BiPh(2,3′,4,5′,6)P5 (1), BiPh-
(2,2′,4,4′,5,5′)P6 (2), BiPh(3,3′,4,4′,5,5′)P6 (3), 6,6′-F2-BiPh-
(3,3′,4,4′)P4 (4), and 1,2,4-dimer (5) (Table 1). Similarly,
galloflavin (11), estramustine phosphate (12), and purpur-
ogallin (10) yielded IC50s for inhibition of Ins(1,3,4)P3
Table 1. Binding and Inhibition Parameters for Ligand-SHIP2 Interaction Measured by Displacement of 2-FAM-InsP5




IC50 (95% confidence values)
phosphate release
IC50 (95% confidence values)
conversion to
Ins(1,3,4)P3 IC50 (95% confidence values)
BiPh(2,3′,4,5′,6)P5 (1) 29 nM (28−31) 3.6 μM (2.6−4.8) 3.4 μM (2.6−4.5)
BiPh(2,2′,4,4′,5,5′)P6 (2) 27 nM (26−29) 1.6 μM (1.2−2.0) 0.9 μM (0.3−2.3)
BiPh(3,3′,4,4′,5,5′)P6 (3) 23 nM (21−25) 1.0 μM (0.8−1.1) 0.7 μM (0.4−1.4)
6,6′-F2-BiPh(3,3′,4,4′)P6 (4) 61 nM (56−67) 19.1 μM (0.4−967) 2.5 μM (0.3−1950)
1,2,4-dimer (5) 31 nM (29−33) 11.0 μM (6.05−20.0) 2.7 μM (0.2−30.8)
Ins(1,3,4,5)P4 2300 nM (2120−2510) N/A N/A
purpurogallin (10) 5.5 μM (4.7−6.4) 89.0 μM (2.14−3696) 7.3 μM (4.5−12.0)
galloflavin (11) not fitted 1.8 μM (1.04 to 3.16) 2.6 μM (2.4−2.8)
estramustine phosphate (12) 35.5 μM (32.4−38.9) not fitted 41.7 μM (18.0−96.3)
5,6,7,8,4′-pentahydroxyflavone
(13)
no displacement 6.0 μM (3.4−10.7) not fitted
AS1949490 (7) interference 1.5 μM (0.3−7.6) not fitted
aFor these experiments, EC50 for 2-FAM-InsP5 binding = 121 nM with displacement measured with polarization set at ca. 215 mP in the absence of
the displacing ligand.
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production of 2.6, 41.7 and 7.3 μM, respectively (Table 1).
Example traces from this HPLC assay are shown for
BiPh(2,2′,4,4′,5,5′)P6 (2) and galloflavin (11) (Figure 5).
The fitted curves for the complete set of biphenyl
compounds and 1,2,4-dimer (5) are shown (Figure S3) and
for other compounds (Figure S4). AS1949490 (7), 5,6,7,8,4′-
pentahydroxyflavone (13), and valrubicin (14) were also
tested (the structures of the drug-like compounds are shown in
Figure S1); valrubicin (14) appeared to be effective, but at the
highest concentrations, it showed deviation from monotonic
behavior, which we think is likely caused by insolubility of the
compound in the assay at the higher concentrations (Figure
S4). Overall, these assays show that galloflavin (11) and
5,6,7,8,4′-pentahydroxyflavone (13) are, by well-used phos-
phate release assays, of similar effect to AS1949490 (7). Like
AS1949490 (7), they do not modify the nature of the inositol
phosphate product of SHIP2 action. Moreover, we show that
metal-complexation HPLC is a powerful test of inhibition of 5-
phosphatase activity.
Crystal structures have been solved for a number of
truncated SHIP2 proteins.18,22,25 However, the only structure
solved with a ligand, other than buffer ions, is that of the
catalytic domain in complex with BiPh(2,3′,4,5′,6)P5 (1)
(PDB 4A9C22). Structures of related 5-phosphatases have
been solved in complex with few ligands and only with the
catalytic domain. Among these ligands, benzene 1,2,4,5-
tetrakisphosphate [Bz(1,2,4,5)P4] (15) and BiPh-
(3,3′,4,4′,5,5′)P6 (3) yielded complexes.22 Our attempts at
cocrystallization of SHIP2cd with the displacing or inhibitory
ligands shown in Figures 1−5 and S1−S4 were without
success. Nevertheless, we were able to solve the structure of
the apoenzyme (PDB, 6SRR), and in crystal soaks with 1,2,4-
dimer (5), we obtained a structure of the complex at 2.27 Å
resolution (PDB, 6SQU) (Figure 6 and Figure S5, Table S2).
The crystal structure of the 1,2,4-dimer-SHIP2cd complex
comprises two monomers of SHIP2 and a single copy of the
inhibitor in the asymmetric unit. The space group (P21) and
cell parameters are essentially isomorphous with those
described previously for the BiPh(2,3′,4,5′,6)P5−SHIP2cd
complex (PDB, 4A9C22) and corresponding apo structure
(PDB, 3NR825). The most striking facet of our structure of the
complex (PDB, 6SQU) is the binding of the ligand in a shallow
pocket distal to the active site (Figure 6A). Superposition of
PDB 4A9C and PDB 6SQU identifies the binding site for
1,2,4-dimer (5) ligand around 15 Å distant from that observed
for BiPh(2,3′,4,5′,6)P5 (1)22 (Figure 6A). With an rmsd of
0.25 Å (247 Cα atoms) between the two inhibitor-bound
structures, ligand binding appears not to promote major
differential conformational changes.
The detailed studies of Le Coq on phosphatase-C2-domain
protein (PDB 5OKM18) have identified how motions of the L4
loop, residues 674−684, contribute to enhanced catalysis of
inositide and phosphoinositide substrates. In particular, they
show that the L4 loop can, in addition to the “closed” (L4-in)
over the active-site pose observed of the phosphatase domain
(PDB, 4A9C22), take alternative open (L4-out) or inter-
mediate poses. The L4 loop harbours an arginine (R682) that
contacts either or both of a pair of aspartic acid residues
(D613/D615) that are adjacent to one end of the α5 helix in
the L4-out conformation. The α5 helix is one of three (α5-7)
that, at the other end, are involved in a network of interactions
via the phosphatase domain residue R649 with the C2 domain.
Thus, the L4-out conformation is stabilized by a relay of
interactions with the C2 domain that offers an explanation of
the significant activation of enzyme for the lipid substrate
afforded by this domain.18
While the distal binding of 1,2,4-dimer (5) does not
significantly modify the L4 closed (L4-in) conformation from
that seen in the complex with BiPh(2,3′,4,5′,6)P5 (1) (Figure
6A), the compound is a potent displacer of 2-FAM-InsP5
(Figure 2) and a potent inhibitor of 5-phosphatase activity
against Ins(1,3,4,5)P4 (Table 1 and Figure S3). The 1,2,4-
dimer (5) does not occupy the positions of the crystallo-
graphically resolved ligands or of the predicted bound states of
docked ligands in catalytic domain or multidomain struc-
tures.18 Indeed, the 1,2,4-dimer (5) ligand fails to directly
contact the L4 loop (Figure 6). Remarkably, we observe that
phosphate P4 of 1,2,4-dimer (5) interacts with D613 (Figure
6B,C). This, we suggest, precludes interaction of this residue
with R682 and adoption of the L4-out conformation that, in its
transient motions, accompanies optimal catalysis.18 Two of the
four residues coordinating 1,2,4-dimer, D613 and E640, are
conserved in SHIP1 (D592 and E622, respectively). The L4-
loop residue R682 is also conservatively replaced with K664
(Figure 6D,E). Given the conservation of the L-4 loop in
SHIP1 and SHIP2, these observations suggest that a common
Figure 3. Inhibition of 2-FAM-InsP5 binding to SHIP2cd. (A)
Displacement by AOD compounds at 10 μM; compounds in red were
taken forward for further analysis. Similar data were obtained for the
NCI Diversity set II. Of these, dose response of inhibition is shown
(B) for purpurogallin (10), (C) for galloflavin, (11), and (D) for
estramustine phosphate (12). Mean values with SD.
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mechanism of inhibition could be shared between SHIP1 and
SHIP2.
A recent study of the closely related enzyme SHIP1 has
proposed, on the basis of docking and site-directed muta-
genesis, that allosteric regulators of the Pelorol family, ZPR-
MN100 (formerly known as AQX-MN100) and ZPR-151,
bind in the interface between the C2 and catalytic domain of
SHIP1.26 The binding site for these ligands is proposed to
include a lysine residue (K681 in PDB entry 6DLG) that is
approximately 23.7 Å distant from D613 coordinated by 1,2,4-
dimer (6SQU) (Figure S6). Thus, while the two allosteric
agents ZPR-MN100 and 1,2,4-dimer occupy distinct sites, they
both point to interdomain (C2-catalytic) communication as a
target for therapeutic manipulation.
To explore the structure-activity relationship of the 1,2,4-
dimer-SHIP2cd interaction, we extended our analysis to close
analogues of the 1,2,4-dimer (5). These include 4,4′-ethane-
1,2-diylbis(oxy)bis(benzene-1,2-bisphosphate) (hereafter
named 1,2-dimer) (16) with fewer phosphates20 and the
respective benzene phosphate monomer units Bz(1,2)P2 (17)
and Bz(1,2,4)P3 (18). Bz(1,2,4)P3 (18) was originally
designed as a structural analogue of Ins(1,4,5)P3.
23 We
included Ins(1,4,5)P3 itself because in an exhaustive study of
Schizosaccharomyces pombe synaptojanin and human SHIP2,
while Ins(1,4,5)P3 was found to be an exemplary substrate of
the former [10-fold better than Ins(1,3,4,5)P4], it proved not
to be a substrate of SHIP2.21 Consistent with this, neither
Ins(1,4,5)P3 nor either of the 1,2- (16) or 1,2,4-dimers (5) or
Bz(1,2)P2 (17) were substrates (Figure 7), but consistent with
our recent study,16 Bz(1,2,4)P3 (18) and Bz(1,2,4,5)P4 (15)
were efficient substrates with an activity of ca. 10% of
Ins(1,3,4,5)P4.
These data begin to dissect the structural requirements for
local allosteric regulation of SHIP2cd. Thus, while among
inositides, the more densely phosphorylated inositol phos-
phates are the strongest substrates [Ins(1,2,3,4,5)P5 is the
strongest],21 so it is also true for simple benzene phosphates16
and, importantly, their formal biphenyl counterparts (Figure
S7). That is to say, biphenyl phosphates are substrates; they
bind in the active site. For the simple benzene phosphate,
Bz(1,2,4)P3 (18), addition of a phosphate to the 5-position
retains catalytic acceptance as does substitution of the 3-
position with a hydroxyl group: 3-OH-Bz(1,2,4)P3 (structure
not shown) and Bz(1,2,4,5)P4 (15) are both progressively
dephosphorylated by SHIP2.16 In contrast, substitution of the
5-position of Bz(1,2,4)P3 (18) with an oxo-linked ethylene
spacer in 1,2,4-dimer (5) renders this molecule a nonsubstrate.
Similar substitution of the 4 = 5 position of Bz(1,2)P2 (17) in
1,2-dimer (16) also did not render catalytic acceptance. The
aforementioned crystallographic studies show that uniquely
among the benzene phosphates, the complete set of biphenyl
phosphate and 1,2,4-dimer ligands tested in crystallographic
screens, 1,2,4-dimer (5) is a ligand of distal (to the active site)
residues including D613. This residue makes a critical
Figure 4. Inhibition of SHIP2cd enzyme activity. Phosphate release from Ins(1,3,4,5)P4 is inhibited by (A) BiPh(2,3′,4,5′,6)P5 (1), (B)
BiPh(2,2′,4,4′,5,5′)P6 (2), (C) BiPh(3,3′,4,4′,5,5′)P6 (3), (D) 6,6′-F2-BiPh(3,3′,4,4′)P4 (4), and (E) 1,2,4-Dimer (5). Mean values with SD.
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contribution to the relay of interactions between the C2-
domain and L4 that confer enhanced turnover of lipids by the
catalytic domain.18 We might speculate that O-methyl or O-
ethyl substitution of Bz(1,2,4)P3 (18) might render this
molecule a local allosteric regulator of SHIP2cd activity, like its
dimer counterpart.
In support of these experiments, we tested the efficacy of the
two dimer compounds and their related benzene phosphate
monomers as displacers of 2-FAM-InsP5 (Figure 7). The IC50s
for these simple benzene phosphate substrates further highlight
the phosphate density dependence of active-site binding:
Bz(1,2)P2 (17), >100 μM; Bz(1,2,4)P3 (18), 6250 nM; and
Bz(1,2,4,5)P4 (15), 390 nM. The InsP analogues of these,
Ins(4,5)P2, Ins(1,4,5)P3, and Ins(1,2,4,5)P4 are not substrates
of SHIP2,21 and Bz(1,2,4)P3 is an inhibitor of the Ins(1,4,5)P3
phosphatase activity of bovine adrenal microsomes.27 Our
experiments confirmed further the potency of the dimers as
SHIP2cd ligands; IC50 for displacement of 2-FAM-InsP5: 1,2-
dimer (16), 1540 nM; 1,2,4-dimer (5), 240 nM (Figure 7).
Overall, the 1,2-dimer (16) and the 1,2,4-dimer (5) exhibit
properties quite distinct from their simple benzene phosphate
homologues and distinct from more densely phosphorylated
biphenyl compounds.16,20,22 That is to say, the dimers are not
substrates (Figure 7) and the 1,2,4-dimer (5) is an inhibitor of
catalytic activity (Table 1, Figures 4, S3) that occupies a distal
(to the active site) regulatory (allosteric) site (Figures 6, S5).
To test the modality of enzyme inhibition by 1,2,4-dimer
(5), the Ins(1,3,4,5)P4 substrate and inhibitor [1,2,4-dimer
Figure 5. Postcolumn metal-complexation HPLC identifies inhibitors of SHIP2 5-phosphatase activity. SHIP2cd-mediated 5-dephosphorylation of
Ins(1,3,4,5)P4 is inhibited by (A) BiPh(2,2′,4,4′,5,5′)P6 (2), (B) galloflavin (11). HPLC separation of substrates and products are shown at
progressively increasing concentrations of inhibitor (C,E,G) BiPh(2,2′,4,4′,5,5′)P6 (2) and (D,F,H) galloflavin (11).
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(5)] were titrated. The results fitted globally to a mixed
inhibition model (Figure 7) yielded a thermodynamic
cooperativity factor α of 0.36. The numerical value of this
parameter is diagnostic of mixed uncompetitive inhibition; for
competitive inhibition, α tends to infinity.28 Thus, 1,2,4-dimer
(5) meets both the kinetic and structural criteria of an
uncompetitive allosteric inhibitor of SHIP2. The Ki value
determined, 4.9 μM, is within the range IC50 (2.7−11 μM)
obtained at a fixed (250 μM) substrate concentration in Table
1. The kcat value obtained (2.3 s−1) is similar to that (1.3 s−1)
Figure 6. An allosteric site on SHIP2cd. (A) Overlay of SHIP2:1,2,4-dimer (5) (PDB 6SQU, green) and SHIP2: BiPh(2,3′,4,5′,6)P5 (1) (PDB
4A9C, gray). Loop L418 is indicated (see text). (B) SHIP2 interactions with 1,2,4-dimer (5). Viewed approximately along the pseudo-twofold axis
relating protein monomers in the asymmetric unit, individual protein monomers are shown in wheat (monomer B) and green (monomer A). (C)
Detail from the superposition of structures PDB 6SQU (green cartoon; orange L4 loop in L4-in conformation) and 5OKM (cyan cartoon; magenta
L4 loop in L4-out conformation). Catalytic residues D607 and H718 are labeled, as is R682 on the L4 loop. Note that D613 adopts two
conformations to interact with either R682 (L4-out conformation) or with the inhibitor 1,2,4-dimer (5) (L4-in conformation). Hydrogen bonds
are shown as dashed lines. Molecular surfaces are shown in wheat. (D) Overlay of SHIP2:1,2,4-dimer (5) (PDB 6SQU, green) and human SHIP1
(PDB 6IBD, blue) in the region of the 1,2,4-dimer binding site. Residues in contact with 1,2,4-dimer in PDB 6SQU are shown in a stick format and
labeled, as are the corresponding residues in PDB 6IBD. Residue R682 in SHIP2 and its partner in SHIP1 are also shown. (E) Clustalw alignment
of human SHIP1 (PDB 6IBD), top sequence, and human SHIP2 (PDB 6SQU), lower sequence. Residues contacting 1,2,4-dimer in PDB 6SQU
are highlighted; conserved or not (blue or red boxes).
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obtained for the catalytic domain by Le Coq and coauthors.18
In the former study, the C2 domain provided an enhancement
of catalysis that was significantly greater for di-C8-PtdIns-
(3,4,5)P3 than for Ins(1,3,4,5)P4, a result consistent with cell
biology that indicates that the principal physiological substrate
in a number of scenarios is most likely PtdIns(3,4,5)P3.
6
Intriguingly, inspection of residual electron density maps for
our refined structure of the complex with 1,2,4-dimer (5) with
SHIP2cd (PDB 6SQU) revealed a small but significant region
of contiguous density in the active site for monomer B. No
comparable residual density is present in monomer A (PDB
6SQU) or in either monomer of our structure of the
apocatalytic domain (PDB 6SRR). The most significant
density lies close to H718, a residue which has been modeled
as contacting the catalytically favoured P5 phosphate of di-C8-
PtdIns(3,4,5)P3 in the phosphatase-C2 structure (PDB
5OKM18). We used the LigandFit approach in the Phenix
software suite29,30 in exhaustive attempts to dock 1,2,4-dimer
(5) to this electron density, but no solutions were found (the
free R-factor rose by 1.52% for the docked solution with the
highest local correlation coefficient). The CC of this solution
was 0.54; a value below 0.6 usually means that the ligand is
misplaced because no suitable density could be found. This
result was unsurprising, given the large disparity in the size and
shape of the density feature compared to that of the inhibitor.
These observations further discount the possibility that the
contiguous electron density observed in the active site of
monomer B (PDB 6SQU) corresponds to a second molecule
of 1,2,4-dimer; indeed, 1,2,4-dimer is an uncompetitive
inhibitor (Figure 7).
As no components of the purification buffers or crystal-
lization solution fitted this density, we next considered what
the SHIP2cd protein may have contacted and potentially
bound prior to its purification from the expression host.
Automated ligand identification in the Phenix software
suite29,30 carries out fitting of a library of 180 of the most
frequently observed ligands in the PDB to residual electron
density in a given map. We employed this procedure together
with the difference electron density map from PDB 6SQU,
yielding a high score (second in the ranked list; Table S3) for
the isoprenoid pyrophosphate-containing compound, farnesyl
diphosphate (local correlation coefficient 0.61, Z-score 1.76).
Given the preference of SHIP2 for phosphoinositide
substrates, pyrophosphate-containing molecules such as the
Figure 7. Substrate preference of SHIP2 for benzene phosphates and related dimers. Benzene phosphates, related molecules, and inositol
phosphate analogues of benzene phosphates are shown; Ins(4,5)P2, Ins(1,4,5)P3, and Ins(1,2,4,5)P4 are not substrates.
21 Catalytic activity toward
compounds is reported as phosphate release, measured at 100 μM substrate and 1 or 10 μM enzyme. The figure additionally shows IC50 values for
displacement of 2-FAM-InsP5. For these experiments, IC50 for 2-FAM-InsP5 binding = 820 nM, with displacement measured with the polarization
set at 125 mP in the absence of the displacing ligand. The bottom-right panel shows inhibition of SHIP2 activity against the Ins(1,3,4,5)P4
substrate by 1,2,4-dimer in the range 0.1−5 μM at an enzyme concentration of 100 nM. The data were fitted by nonlinear least squares regression
to a mixed inhibition model in GraphPad v6. Values for enzymatic activity are means and standard deviation of four measurements.
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FPP precursors geranyl pyrophosphate (GPP) (19) and
isopentenyl pyrophosphate (IPP) (20) (Figure 8) were also
considered as possible ligands. Automated fitting of these with
Phenix resulted in local correlation coefficients of 0.66 and
0.52, respectively. The fit of geranyl pyrophosphate to active
site residual electron density of PDB 6SQU is shown (Figure
S8). We did not crystallographically refine these models as we
have no independent evidence for ligand presence in the
crystal. We did, however, undertake phosphate release assays,
proffering GPP (19), IPP (20) and pyrophosphate as
substrates for SHIP2cd. Our results demonstrate that these
molecules can indeed bind in the active site and act as
substrates (Figure 8A). We were unable to assay FPP due to a
high-phosphate background. Phosphate release from both GPP
(19) and IPP (20) at a concentration of 1 mM was found to be
similar to that of di-C8-PtdIns(3,4,5)P3 at 250 μM (Figure
8A). Although there is no published evidence that GPP (19) is
a physiological substrate, it is interesting that the SHIP2cd
domain can bind and utilize pyrophosphate molecules with
lipid-like methylene tails. Thus, while it is clear that GPP (19)
is a substrate of SHIP2cd, the identity of the bound moiety
(moieties) remains unresolved. While the C2-Ptase apo
structure (PDB 5OKM) has limited active-site density that
has been modeled to water(s),18 we note that GPP can be
docked to the residual active site density in the human SHIP2
apo structure (PDB 3NR8), albeit in a different orientation to
that shown for PDB 6SQU (Figure S8). One intriguing
possibility is that a previously unrecognized substrate or
product is evident in the 1,2,4-dimer (5)-liganded structure.
The foregoing structural and enzymological studies highlight
a range of approaches and experimental observations that
could enable medicinal chemistry interventions on SHIP2.
PtdIns(3,4,5)P3 signaling in multiple myeloma has been shown
to be an accessible system for study of small molecule targeting
of SHIP1/2 function.6 We sought to test the efficacy of the
putative SHIP2 inhibitors identified above in a multiple
myeloma context. Interleukin 6 (Il-6) is a peptide growth
factor that supports cell survival of multiple myeloma cells
which express multiple PI3K isoforms constitutively.31 Il-6-
treatment of multiple myeloma cells and cell lines activates Akt
by phosphorylation of S473, and this can be blocked by
inhibition of PI3Kδ/γ with the dual PI3K PI3Kδ/γ inhibitor
duvesilib or by lentiviral knockdown of combined PI3Kδ/γ.32
A cartoon of the pathway is shown in Figure 9A.
We treated serum-starved MM1 cells (a multiple myeloma
cell line) with Il-6, as a positive control, and with the
inhibitors, initially at 10 μM concentration, limiting treatment
to 30 min, a period avoiding large-scale apoptosis. We included
the known commercially available SHIP2 inhibitor AS1949490
(7).14 We blotted for pAkt S473 and total Akt. Initial
experiments revealed little effect of purpurogallin (10),
galloflavin (11), estramustine phosphate (12), pentahydroxy-
flavone (13), or biphenyl 2,3′,4,5′,6-pentakisphosphate (1),
but revealed a notable effect for AS1949490 (7). Repeat
experiments with purpurogallin (10) and AS1949490 (7)
showed that AS1949490 (7) reduced Akt phosphorylation
(isoform unresolved) in a dose-dependent manner (Figure 9B)
and markedly reduced cell survival (Figure 9D). While
purpurogallin (10) was without marked effect on Akt
phosphorylation (at 30 min), it abrogated the enhancement
of cell survival at 24 h afforded by Il-6, reducing survival to
control levels (Figure 9B,C). These data do not fit a simple
model of PtdIns(3,4,5)P3 as an exclusive cell survival signal in
MM1 cells since elevation of PtdIns(3,4,5)P3 might be
expected to increase Akt phosphorylation.14 Rather, we note
evidence that different Akt isoforms are differentially activated
in a spatiotemporal context by either and/or both PtdIns-
(3,4,5)P3 and PtdIns(3,4)P2,
33 reflecting direct activation of
Akt by PtdIns(3,4)P2
34 and correlation of PtdIns(3,4,5)P3 and
PtdIns(3,4)P2 levels, respectively, with phosphorylation of Akt
on Thr308 and Ser473.35 Indeed, in the context of PDGF
signaling in NIH 3T3 cells, AS1949490 (7) reduced
PtdIns(3,4)P2 levels specifically in the plasma membrane,
reducing recruitment of Akt2 and sorting of PtdIns(3,4)P2 to
early endosomes.33 Similarly and specifically in the context of
multiple myeloma, pan-SHIP1/2 inhibitors have been shown
Figure 8. Catalytic activity of SHIP2 toward isoprenoids. (A) Structures of isoprenoids and di-C8-PtdIns(3,4,5)P3 substrates. (B) Phosphate release
from di-C8-PtdIns(3,4,5)P3 geranyl pyrophosphate, GPP (19); isopentenyl pyrophosphate, IPP (20); sodium pyrophosphate, NaPP; (mean and
s.d.).
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to kill multiple myeloma cells and in a SHIP2-expressing breast
cancer cell reduced cell numbers.36 Consequently, our data are
consistent with more comprehensive studies and reviews of
SHIP1/2 function in immune cell context that point to
therapeutic utility of SHIP1/2 inhibitors.4,11,36,37
■ CONCLUSIONS
By use of orthogonal assays and a powerful fluorescent active-
site ligand displacement strategy,16,19 we have defined a
regulatory site on the catalytic domain of SHIP2. Occupancy
of this site by 1,2,4-dimer (5) inhibits catalytic activity against
Ins(1,3,4,5)P4 in an uncompetitive manner. The ligand
coordinates an aspartate residue on the L4 loop that is part
of a network of intramolecular interactions between the C2-
domain and the phosphatase domain.18 The shallow pocket
occupied by the ligand provides a potential target for fragment-
based screening approaches for novel inhibitors of SHIP2.
These might need to be structurally extended in nature in line
with the 1,2,4-dimer (5) and most ideally without any
phosphate groups. The structurally validated approach of use
of fluorescent active site ligands as a screening tool should
assist facile robotic screening of larger compound libraries for
modulators of the SHIP2 function. Extension of the screen to
multidomain SHIP2 protein should readily allow identification
of allosteric modulators whose binding lies on other domains
of the protein. Quite separately, the discovery of GPP (19) and
IPP (20) as potential ligands and substrates of SHIP2 is
tantalizing, given the role of inactivating mutations of SHIP2 in
opsismodysplasia, a skeletal chondroplasia,38 and the use of
bisphosphonates, which target isoprenoid metabolism to
prevent bone resorption.39
■ EXPERIMENTAL SECTION
Chemicals. Ins(1,3,4,5)P4 was prepared according to ref 40.
Ins(1,3,4)P3 and Ins(1,4,5)P3 were obtained from AG Scientific as K
+
salts. Ins(3,4,5)P3 was obtained from SiChem as Na
+ salt. All biphenyl
phosphates and related compounds were prepared as described23,24 or
in a very similar fashion. AS 1949490 (7) was obtained from Tocris.
Sodium pyrophosphate, geranyl pyrophosphate, and isopentenyl
pyrophosphate were obtained from Sigma-Aldrich. Di-C8-PtdIns-
(3,4,5)P3 was obtained from Echelon Biosciences.
All compounds biologically evaluated had >95% purity, as
determined by reverse-phase hplc on a 4.6 × 250 mm Phenomenex
Synergi Hydro-RP column eluted isocratically at 1 ml.min−1 with a
solvent mixture comprising 4 mM tetrabutylammonium hydroxide in
70/30, v/v, 50 mM NaH2PO4/(acetonitrile/MeOH/water, 40/50/10,
v/v/v). Samples, 10 μL of 10 μM compound, were injected, and peaks
were detected with a Jasco FP-950 fluorescence detector set at Ex 285
nm, Em 320 nm and gain 10.
Protein Purification. An expression clone of human INPPL1cd
(SHIP2 catalytic domain, residues 419−832 in the vector pNIC-
MBP) was obtained from Source BioScience (clone accession
TC124029). Recloning, expression, and purification were performed
as described.16
Docking Simulations. Docking simulations were performed as
described19 with the SHIP2 catalytic domain (SHIP2cd) as an
inflexible receptor and 2-FAM-InsP5 as a flexible ligand.
Crystallization, Data Collection, and Refinement. Crystals
were grown in 0.5 μL sitting drops at 16 °C, equilibrated against a
reservoir containing 50 μL of the precipitant (0.17 M ammonium
sulfate, 25.5% PEG 4000, 15% glycerol). Protein at 10 mg/mL was
mixed with an equal volume of the precipitant. Single crystals were
soaked for 6 min in a 1 μL drop containing 0.17 M ammonium
sulfate, 25.5% PEG 4000, 15% glycerol, and 6.8 mM 5,5′-ethane-1,2-
diylbis(oxy)bis(benzene-1,2,4-trisphosphate) (1,2,4-dimer) (5), and
flash-frozen in liquid nitrogen. X-ray diffraction data were collected on
beamline I03 at the Diamond Light Source (Oxford). Molecular
replacement and refinement were carried out using Phenix,41 and
manual rebuilding was performed using Coot.42 Automated
identification and placement of ligands was carried out using the
ligand_identification facility in Phenix.29,30
Fluorescence Polarization Screening of SHIP2. The method
used was as described in ref 19 using a 20 mM HEPES pH 7.3, 50
mM KCl, 1 mM EDTA buffer. Screening assays were performed by
hand at 100 nM SHIP2, 5 nM 2-FAM-InsP5, and 10 μM screen
compound using NCI Diversity set II, Developmental Therapeutics
Program NCI/NIH, and the NCI Approved Oncology Drug (AOD)
Set screens in 96-well black plates on a ClarioStar (BMG Ltd) plate
reader. Displacement assays were performed using 100 nM SHIP2cd
and 2 nM 2-FAM-InsP5 1 in 384-well black plates. Polarization values
were fitted to a four-parameter logistic in GraphPad Prism v6.0 after
export from the MARS software of the plate reader.
Phosphate Release Assays. Enzyme reactions containing 100
nM SHIP2cd, 250 μM Ins(1,3,4,5)P4, and inhibitor (100 nM−100
μM) in 20 mM HEPES pH 7.3, 50 mM KCl, 1 mM EDTA buffer
were incubated for 20 min at 30 °C. In a 96-well plate, 10 μL of the
enzyme reaction mixture was mixed with 10 μL of the color reagent [4
parts 1.5% w/v ammonium molybdate in a 5.5% v/v sulfuric acid
solution; 1 part 10.8% w/v iron(II) sulfate solution]. After 10 min
incubation at room temperature, absorbance at 700 nm was measured
Figure 9. Inhibition of IL6-induced cell survival of MM1 by
AS1949490 (7). (A) Cartoon of SHIP2 involvement in PI3K/Akt
signaling in multiple myeloma cells. Il-6 activates Akt by mechanisms
including specific phosphorylation of S473, the action of Il-6,
including phosphorylation of S473, is blocked by inhibition of
SHIP2. (B) pAKT S473 and total AKT levels in serum-starved MM1
cells (control) and cells treated for 30 min with 10ng mL−1 Il-6 in the
presence or not of either purpurogallin (10) or AS1949490 (7).
(C,D) Cell viability was measured after 24 h (mean and s.e.).
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using a Hidex Sense (LabLogic Systems, UK) microplate reader.
Measurements of background buffer absorbance were subtracted from
the absorbance values and the resulting values converted to phosphate
by reference to a standard curve constructed with 1−50 μM KH2PO4.
Results were plotted and fitted to a four-parameter logistic using
GraphPad Prism v6.0. For analysis of the modality of enzyme
inhibition by 1,2,4-dimer (5), assays were performed in the same
buffer with 100 nM SHIP2cd, varying Ins(1,3,4,5)P4, and inhibitor.
Reactions were performed for 35 min at 30 °C. Results were fitted
globally to a mixed model in GraphPad Prism version 6 for analysis of
kinetic parameters and the thermodynamic cooperativity factor.28
HPLC Assay of Active-Site Binding of 2-FAM-InsP5. Assays to
determine whether SHIP2 can dephosphorylate 2-FAM-InsP5 were
performed by incubating 100 nM SHIP2cd with 50 μM 2-FAM-InsP5
in 20 mM HEPES pH 7.3, 1 mM EDTA buffer, pH 7.3, overnight at
25 °C. Aliquots (20 μL) of the reaction products were diluted to 50
μL, and a 20 μL sample was analyzed by HPLC on a 3 mm i.d. A
CarboPac PA200 column was eluted with methanesulfonic acid.43
Substrates and products were detected with a Jasco FP-920
fluorescence detector set at Ex485 nm, 10 nm band pass; Em520
nm, 10 nm band pass, and a gain of 10. Data were exported from
ChromNav v1.0 software of the Jasco HPLC machine as ASCII files
and redrawn with GraphPad Prism v6.0.
HPLC Assay of 5-Phosphatase Activity of SHIP2. Enzyme
reactions from the phosphate release assays performed as described
above with 250 μM Ins(1,3,4,5)P4 were also analyzed by HPLC.
Reactions of 10 μL were stopped by the addition of EDTA to 5 mM,
diluted with water to 50 μL, and a 20 μL aliquot injected onto a 3 mm
i.d. CarboPac PA200 column (Dionex, UK) eluted with a gradient of
methanesulfonic acid. Inositol phosphates were detected by
postcolumn complexation with ferric nitrate.43 Peak areas were
integrated in the ChromNav v2.0 software of the Jasco HPLC
machine. For verification of the reaction catalyzed by SHIP2, inositol
trisphosphates were spiked into reaction products to a final (injected)
concentration of 50−200 μM (Figure S1). For reproduction of
chromatograms, data were exported from the ChromNav2 software as
x,y data files and redrawn in GraphPad Prism v6.0.
Biological Methods. Antiphosphorylated and pan Akt antibodies
were purchased from Cell Signalling Technology (Cambridge, MA,
USA). Interleukin-6 (Il-6) was purchased from Miltenyi Biotec
(Auburn, CA, USA).
The authenticated multiple myeloma-derived cell line MM1 was
obtained from the European Collection of Cell Cultures and was
cultured in RPMI 1640 medium supplemented with 10% foetal
bovine serum, penicillin, and streptomycin (all obtained from
Invitrogen, Paisley, UK).44
Cell viability was determined after 24 h using Cell Titre GLO
(Promega, Southampton, UK).31 Data were normalized to vehicle
controls. All data points are represented as the mean with s.e.
Western Immunoblotting. Sodium dodecyl sulphate polyacryl-
amide gel electrophoresis and western blot analyses were performed,
as described previously.44
Data Analysis. Dose−response relationships were fitted to Hill
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takisphosphate (triethylammonium salt); 3AC, 3α-amino-
cholestane; 6,6′-F2-BiPh(3,3′,4,4′)P4, 6,6′-difluoro biphenyl-
3,3′,4,4′-tetrakisphosphate; Bz(1,2)P2, benzene 1,2-bisphos-
phate; Akt, protein kinase B; Bz(1,2,4)P3, benzene 1,2,4-




akisphosphate; EC50, half-maximal effective concentration;
EDTA, ethylenediamine tetra-acetic acid; GPP, geranyl
pyrophosphate; HEPES, 4-(2-hydroxyethyl)-1-piperazine-
ethane sulfonic acid; His, histidine; HPLC, high-pressure
liquid chromatography; IC50, half-maximal inhibitory concen-
tration; IL-6, interleukin 6; INPP5A, type I inositol 5-
phosphatase; INPP5B, type II inositol 5-phosphatase;
INPP5E, inositol polyphosphate 5-phosphatase E; Ins(4,5)P2,
1 d-myo-inositol 4,5-bisphosphate; Ins(1,3,4)P3, 1d-myo-
inositol 1,3,4-trisphosphate; Ins(1,4,5)P3, 1d-myo-inositol
1,4,5-trisphosphate; Ins(3,4,5)P3, 1d-myo-inositol 3,4,5-tri-
sphosphate; Ins(1,2,4,5)P4, 1d-myo-inositol 1,2,4,5-tetraki-
sphosphate; Ins(1,3,4,5)P4, 1D-myo-inositol 1,3,4,5-tetraki-
sphosphate; IP3R, Ins(1,4,5)P3 Receptor; IPP, isopentenyl
pyrophosphate; OCRL-1, Lowe oculocerebrorenal syndrome
protein (INPP5F); pAkt, phosphorylated Akt; PDGF, platelet-
derived growth factor; PtdIns4P, phosphatidyl 1d-myo-inositol
4-monophosphate; PtdIns(3,4)P2, phosphatidyl 1d-myo- in-
ositol 3,4-bisphosphate; PtdIns(3,4,5)P3, phosphatidyl 1D-myo-
inositol 3,4,5-trisphosphate; SHIP1, SH2 domain-containing
inositol 5-phosphatase type 1; SHIP2, SH2 domain-containing
inositol 5-phosphatase type 2; SKIP1 (INPP5K), inositol
polyphosphate 5-phosphatase K; SYNJ1, synaptojanin-1;
SYNJ2, synaptojanin-2
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